Last updated: April 7, 2025
Sponsor: Montefiore Medical Center
Overall Status: Active - Recruiting
Phase
4
Condition
Pain (Pediatric)
Dyskinesias
Dystonias
Treatment
DaxibotulinumtoxinA
Clinical Study ID
NCT06195241
2023-15151
2023-IST-DAXI-000186
Ages > 18 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Benign essential blepharospasm (BEB) or hemifacial spasm (HFS) as diagnosed by anophthalmologist.
No known neurologic or neuromuscular systematic medications.
No history or surgical intervention for BEB or HFS.
Exclusion
Exclusion Criteria:
- Patients will be excluded if age < 18, are pregnant, non-willing, or withcontra-indications to botulinum toxin.
Study Design
Total Participants: 40
Treatment Group(s): 1
Primary Treatment: DaxibotulinumtoxinA
Phase: 4
Study Start date:
February 11, 2025
Estimated Completion Date:
March 31, 2027
Study Description
Connect with a study center
Montefiore Medical Center
Bronx, New York 10466
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.